WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561226

CAS#: 831217-01-7

Description: Acetildenafil is a synthetic drug which acts as a phosphodiesterase inhibitor. It is an analog of sildenafil (Viagra) which has been detected in numerous different brands of supposedly "herbal" aphrodisiac products sold to boost libido and alleviate erectile dysfunction.

Chemical Structure

CAS# 831217-01-7

Theoretical Analysis

MedKoo Cat#: 561226
Name: Acetildenafil
CAS#: 831217-01-7
Chemical Formula: C25H34N6O3
Exact Mass: 466.2692
Molecular Weight: 466.59
Elemental Analysis: C, 64.36; H, 7.35; N, 18.01; O, 10.29

Price and Availability

Size Price Availability Quantity
1.0mg USD 235.0 2 Weeks
5.0mg USD 540.0 2 Weeks
10.0mg USD 900.0 2 Weeks
25.0mg USD 1565.0 2 Weeks
Bulk inquiry

Synonym: Acetildenafil; Hongdenafil

IUPAC/Chemical Name: 5-[2-Ethoxy-5-[2-(4-ethylpiperazin-1-yl)acetyl]phenyl]-1-methyl-3-propyl-4H-pyrazolo[4,3-d]pyrimidin-7-one


InChi Code: InChI=1S/C25H34N6O3/c1-5-8-19-22-23(29(4)28-19)25(33)27-24(26-22)18-15-17(9-10-21(18)34-7-3)20(32)16-31-13-11-30(6-2)12-14-31/h9-10,15H,5-8,11-14,16H2,1-4H3,(H,26,27,33)


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 466.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Dhariwal AK, Bavdekar SB. Sildenafil in pediatric pulmonary arterial hypertension. J Postgrad Med. 2015 Jul-Sep;61(3):181-92. doi: 10.4103/0022-3859.159421. Review. PubMed PMID: 26119438; PubMed Central PMCID: PMC4943407.

2: Perez KM, Laughon M. Sildenafil in Term and Premature Infants: A Systematic Review. Clin Ther. 2015 Nov 1;37(11):2598-2607.e1. doi: 10.1016/j.clinthera.2015.07.019. Epub 2015 Oct 19. Review. PubMed PMID: 26490498.

3: Doumas M, Lazaridis A, Katsiki N, Athyros V. PDE-5 inhibitors: clinical points. Curr Drug Targets. 2015;16(5):420-6. Review. PubMed PMID: 25392015.

4: Radulova P, Vakrilova L, Slancheva B. [BRONCHOPULMONARY DYSPLASIA--WHAT DO WE KNOW TODAY?]. Akush Ginekol (Sofiia). 2015;54(9):37-43. Review. Bulgarian. PubMed PMID: 26863795.

5: Malleske DT, Yoder BA. Congenital chylothorax treated with oral sildenafil: a case report and review of the literature. J Perinatol. 2015 May;35(5):384-6. doi: 10.1038/jp.2015.10. Review. PubMed PMID: 25917021.

6: Ganzevoort W, Alfirevic Z, von Dadelszen P, Kenny L, Papageorghiou A, van Wassenaer-Leemhuis A, Gluud C, Mol BW, Baker PN. STRIDER: Sildenafil Therapy In Dismal prognosis Early-onset intrauterine growth Restriction--a protocol for a systematic review with individual participant data and aggregate data meta-analysis and trial sequential analysis. Syst Rev. 2014 Mar 11;3:23. doi: 10.1186/2046-4053-3-23. Review. PubMed PMID: 24618418; PubMed Central PMCID: PMC3975177.

7: Igarashi A, Inoue S, Ishii T, Tsutani K, Watanabe H. Comparative Effectiveness of Oral Medications for Pulmonary Arterial Hypertension. Int Heart J. 2016 Jul 27;57(4):466-72. doi: 10.1536/ihj.15-459. Epub 2016 Jul 7. Review. PubMed PMID: 27385603.

8: Herrick AL. Recent advances in the pathogenesis and management of Raynaud's phenomenon and digital ulcers. Curr Opin Rheumatol. 2016 Nov;28(6):577-85. doi: 10.1097/BOR.0000000000000332. Review. PubMed PMID: 27541182.

9: Lu X, Han H, Xing N, Tian L. [Efficacy of sildenafil citrate in men with erectile dysfunction following bilateral nerve-sparing radical prostatectomy: systematic review and meta-analysis]. Zhonghua Yi Xue Za Zhi. 2015 Sep 22;95(36):2964-8. Review. Chinese. PubMed PMID: 26814076.

10: Magee AG, Makhecha S, Bentley S. Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children. Expert Opin Drug Saf. 2015 May;14(5):633-42. doi: 10.1517/14740338.2015.1022527. Epub 2015 Mar 7. Review. PubMed PMID: 25746065.

11: Sands JM, Klein JD. Physiological insights into novel therapies for nephrogenic diabetes insipidus. Am J Physiol Renal Physiol. 2016 Dec 1;311(6):F1149-F1152. doi: 10.1152/ajprenal.00418.2016. Epub 2016 Aug 17. Review. PubMed PMID: 27534996; PubMed Central PMCID: PMC5210200.

12: Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2013 Oct;72(10):1696-9. doi: 10.1136/annrheumdis-2012-202836. Epub 2013 Feb 20. Review. PubMed PMID: 23426043.

13: Peregud-Pogorzelska M, Kornacewicz-Jach Z. [Pregnant woman with pulmonary hypertension]. Przegl Lek. 2015;72(4):193-5. Review. Polish. PubMed PMID: 26455018.

14: Oldenburger NJ, Mank A, Etnel J, Takkenberg JJ, Helbing WA. Drug therapy in the prevention of failure of the Fontan circulation: a systematic review. Cardiol Young. 2016 Jun;26(5):842-50. doi: 10.1017/S1047951115002747. Epub 2016 Mar 7. Review. PubMed PMID: 26947621.

15: Trenor CC 3rd. Medical management of vascular anomalies. Semin Cutan Med Surg. 2016 Sep;35(3):177-81. doi: 10.12788/j.sder.2016.046. Review. PubMed PMID: 27607327.

16: Zhang H, Wang X. Priming the proteasome by protein kinase G: a novel cardioprotective mechanism of sildenafil. Future Cardiol. 2015 Mar;11(2):177-89. doi: 10.2217/fca.15.3. Review. PubMed PMID: 25760877; PubMed Central PMCID: PMC4370174.

17: Efremov EA, Kasatonova EV, Mel'nik JI. [USE OF SILDENAFIL CITRATE FOR TREATMENT OF ERECTILE DYSFUNCTION OF VARIOUS ETIOLOGY]. Urologiia. 2015 Mar-Apr;(2):117-8, 120-1. Review. Russian. PubMed PMID: 26237819.

18: Gao L, Yang L, Qian S, Li T, Han P, Yuan J. Systematic review and meta-analysis of phosphodiesterase type 5 inhibitors for the treatment of female sexual dysfunction. Int J Gynaecol Obstet. 2016 May;133(2):139-45. doi: 10.1016/j.ijgo.2015.08.015. Epub 2015 Dec 17. Review. PubMed PMID: 26797204.

19: Kukreja RC. Sildenafil and cardioprotection. Curr Pharm Des. 2013;19(39):6842-7. Review. PubMed PMID: 23590161.

20: Beltrán-Gámez ME, Sandoval-Zárate J, Pulido T. [Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension]. Arch Cardiol Mex. 2015 Jul-Sep;85(3):215-24. doi: 10.1016/j.acmx.2015.03.001. Epub 2015 Jun 2. Review. Spanish. PubMed PMID: 26047999.